

AD _____

Award Number DAMD17-98-1-8023

TITLE: Alternative DNA Damage Checkpoint Pathways in Eukaryotes

PRINCIPAL INVESTIGATOR: Yi-Chen J. Li, Ph.D.

CONTRACTING ORGANIZATION: Baylor College of Medicine
Houston, Texas 77030-3498

REPORT DATE: April 1999

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4

19991020 056

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE April 1999	3. REPORT TYPE AND DATES COVERED Annual Summary (23 Mar 98 - 22 Mar 99)	
4. TITLE AND SUBTITLE Alternative DNA Damage Checkpoint Pathways in Eukaryotes			5. FUNDING NUMBERS DAMD17-98-1-8023	
6. AUTHOR(S) Yi-Chen J. Li, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine Houston, Texas 77030-3498			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) The goals of this grant are to perform a mutagenesis screen to identify the genes in the alternative DNA damage checkpoint pathway in yeast, to characterize and clone these genes, and to isolate and analyze the human counterparts of these genes. During the first year of this grant, we have constructed a <i>cdc9-8</i> , <i>rad9Δ</i> double mutant strain SCP2, which is both temperature-sensitive at 30°C and UV-sensitive, for the mutagenesis screen. Approximately 220,000 colonies of SCP2 have been mutagenized by EMS and screened for temperature-sensitivity at 30°C. This primary screen yields three temperature-sensitive mutants, <i>chb13</i> , <i>chb16</i> , and <i>chb57</i> . A secondary UV sensitivity screen was also performed on these three <i>chb</i> mutants. In summary, <i>chb13</i> is a strong mutant that can no longer be rescued by <i>CHES1</i> in both temperature- and UV-sensitivity. The other two mutants have only one strong phenotype. Specifically, <i>chb16</i> is highly temperature-sensitive but only moderately UV-sensitive, whereas <i>chb57</i> is very sensitive to UV but not as sensitive to high temperature. Our next goal is cloning the genes mutated in these three strains.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 7	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Li

PI - Signature

15 Apr 99
Date

Progress Report (March 1998 to March 1999)

Technical Objective 1-1

Perform a comprehensive mutagenesis screen in *S. cerevisiae* to isolate yeast mutant strains which have defective checkpoint bypass genes

Our working hypothesis is that *CHES1* suppresses the radiation sensitivity of *mec1-1* and *rad9Δ* by activation of an alternative DNA damage-induced G2 checkpoint pathway in *S. cerevisiae*. The genes in the pathway can be identified genetically. The ultimate objectives of this grant proposal are to identify, characterize, and clone the genes in this alternative pathway, and to isolate the human homologs of these genes and analyze their structure and expression in human breast cancer derived cell lines and human breast tumor samples. The goals of the first year of this grant are to develop a temperature sensitive strain, to optimize mutagenesis conditions, and to accomplish a mutagenesis screen to identify mutant strains that can no longer be rescued by *CHES1* in the absence of wild type *RAD9*.

The method proposed in this project utilizes a temperature sensitive strain that does not grow at 30°C and is sensitive to UV irradiation. This requires the combination of *cdc9-8* and *rad9Δ* mutations in the same genome. The *rad9Δ* not only lowers the permissive temperature of *cdc9-8* from 30°C to 23°C, but also provides the UV sensitive phenotype. The *cdc9-8* gene was gap repaired out from the 9085-1-10-4 strain and put onto an integration vector with *URA3* marker. The plasmid was then introduced into a *rad9Δ* strain (Y438 from the Elledge's laboratory) and plated onto URA deficient- and 5-FOA media sequentially. This allowed isolation of a strain where the *cdc9-8* allele replaces the wild type *CDC9* to generate the double mutant strain SCP2.

Different amount of EMS, ranging from 0 to 50 μl, was tested to assay for optimal mutagenesis. We chose 5 μl for it gave approximately 50% killing in SCP2. The mutagenesis screen was carried out by a slightly modified method to the one originally described in the application. Specifically, SCP2 was transformed with two plasmids, each carrying *CHES1* or *RAD9* genes, before EMS mutagenesis. After exposure to EMS, the cells were washed and plated onto selective medium at 30°C. Since the cells still contain wild type *RAD9* at this point, they are able to grow at 30°C. The mutants were replica-plated to 5-FOA to select against the *RAD9* plasmid and screened for growth at 23°C but not at 30°C. The tentative name assigned to the qualified mutants is *chb* for checkpoint bypass. The colonies identified on this first pass were then patched and replica-plated to test for temperature sensitivity more carefully at 37°C, 32°C, 30°C, and room temperature. The clones, which no longer grew at 30°C from the second temperature sensitivity test, were subject to a secondary screen to determine if they have also lost the response of *CHES1* after UV irradiation. Our model predicts that checkpoint bypass gene mutants should be UV sensitive even when *CHES1* is present in this *rad9Δ* strain. The UV sensitivity screen was performed by quantifying the survival rate after exposure to 10 J/m² of UV radiation, in comparison to the survival rate of the parental strain transformed with either empty vector or *CHES1*-containing plasmid.

We have mutagenized and screened approximately 220,000 clones and 310 putative temperature sensitive clones were picked originally. The majority of clones

failed on the second temperature sensitivity test, leaving three strong candidates that are truly temperature sensitive in the presence of *CHES1* when the *RAD9* plasmid was lost. Among those, *chb13* and *chb16* are highly temperature sensitive whereas *chb57* is a weaker allele. With regard to UV sensitivity, *chb13* and *chb57* are also sensitive to UV radiation but the effect of *chb16* is intermediate when compared to the controls (figure 1). The growth of *chb16* is slower than the other two *chb* strains, therefore, *chb16* is a relatively unhealthy mutant in general. Overall, *chb13* appears to be a very strong mutant that has lost all response to *CHES1* by our assays. Both *chb16* and *chb57* are moderate mutants that have one strong phenotype. The results of this mutagenesis screen are summarized in table 1. Construction of a *cdc9-8* and *rad9Δ* double mutant strain of the opposite mating type is underway in order to perform complementation analysis to determine whether the mutants are dominant or recessive. Once defined, we will clone the genes that were recessively mutated in the *chb* strains by introducing a *S. cerevisiae* genomic library into the mutant strain and selecting for growth at 30°C in the presence of *CHES1*.

Our previous results showed that a *chk1* mutant is at least partially defective in the response to *CHES1* (D. Pati, unpublished data). This suggests that *CHK1* maybe a candidate gene in the proposed alternative pathway. We will test all three *chb* mutants for the complementation by *CHK1*. Disruption of *CHK1* in the parental strain SCP2 is also underway for the comparison of the phenotypes with these *chb* mutants.

The analysis of these mutants has also allowed us to confirm that the *CHES1*-dependent pathway is partially parallel to the *RAD9*-dependent pathway. Our previous data showed that *CHES1* could either act on a gene product downstream of *DUN1* in the primary *MEC1*-dependent pathway or, more likely, activate an alternative pathway (Pati *et al.*, 1997). Consistent with the parallel pathway model, introduction of a wild type *RAD9* gene restores UV resistance to the SCP2 strain and all three mutants. Since the *chb* mutants are UV resistant when *RAD9* is present on the episome, they are apparently not simply downstream of *RAD9*. This favors the alternative parallel pathway model. Our current model for the *CHES1* activated checkpoint is demonstrated in figure 2.

In the "Statement of Work" attached to the original proposal, the task for the first year was to finish both the primary temperature sensitivity screen and the secondary UV sensitivity screen. These have been completed.

Reference

- D. Pati, C. Keller, M. Groudine, and S. E. Plon. 1997. Reconstitution of a *MEC1*-independent Checkpoint in Yeast by Expression of a Novel Human *fork head* cDNA. *Mol. Cell. Biol.* 17: 3037-3046.




Figure 1 – Results of secondary assay of three *chb* mutants identified in the large-scale mutagenesis screen. The percent survival after exposure to 10 J/m² is shown for the parental *rad9Δ* strain with a control vector or *CHES1* and the three *chb* mutant strains with *CHES1*.

Strain	Growth at 30°C	Survival after 10 J/m ² UV irradiation
<i>rad9Δ, cdc9-8</i> + Vector	-	7.0%
<i>rad9Δ, cdc9-8</i> + <i>CHES1</i>	+++	20.5%
<i>rad9Δ, cdc9-8, chb13</i> + <i>CHES1</i>	-	8.9%
<i>rad9Δ, cdc9-8, chb57</i> + <i>CHES1</i>	+	6.7%
<i>rad9Δ, cdc9-8, chb16</i> + <i>CHES1</i>	-	15.1%

Table 1 – Summary of both primary and secondary screens for mutants obtained in the mutagenesis screen.




Figure 2 – Current Model of *CHES1* Dependent Checkpoint Pathway.